Trump has not received hydroxychloroquine since he tested positive for the coronavirus. And why would he? It’s a potentially dangerous treatment
- matchingmole
- 10-07-2020, 12:43 PM
- oeb11
- 10-07-2020, 12:49 PM
You are not a physician - Thank God for That!!!
And - neither is Trump.
And - neither is Trump.
- matchingmole
- 10-07-2020, 12:54 PM
Yes I am
As your doctor....I advise you to go to Venezuela...and plot your Civil War with comrade XI
As your doctor....I advise you to go to Venezuela...and plot your Civil War with comrade XI
- HedonistForever
- 10-07-2020, 01:05 PM
He already took HC. It didn't harm him then so how dangerous could it be? HC was one of the earliest drugs used at a time when doctors didn't know if anything would work. The experts decided that a drug that has been used by a billion people in 55 years posed an acceptable risk when used with prescription from a doctor that could monitor the patient. At no time was it ever suggested that anybody sitting at home should use HC without a doctors referral but as we have seen many people like mm, it's just to juicy a narrative to let go of because of the confusion surrounding the use. A use by the way still use by some doctors in foreign countries precisely because of it's abundance and the fact that there is no evidence at all of wide spread deleterious effects when used by a doctor that can monitor their patient.
https://www.prnewswire.com/news-rele...301098030.html
July 22, 2020 /PRNewswire/ -- This week the Association of American Physicians & Surgeons submitted additional evidence to a federal court for why interference with hydroxychloroquine (HCQ) should end by the Food & Drug Administration (FDA) and the Department of Health & Human Services (HHS), in AAPS v. FDA, No. 1:20-cv-00493-RJJ-SJB (W.D. Mich.).
"As confirmed by another recent study of thousands of patients at the Henry Ford Health System in Michigan, HCQ is both very safe and highly effective in treating COVID-19, reducing mortality by 50%," AAPS informed the court in its filing. "Countries with underdeveloped health care systems are using HCQ early and attaining far lower mortality than in the United States, where [HHS and the FDA] impede access to HCQ."
Yet most Americans are still unable to obtain HCQ for early treatment of COVID-19, and virtually no Americans are able to access it as preventive medicine. HCQ has been used safely for decades by travelers to protect against malaria, but Americans are dying from COVID-19 while HCQ is withheld from them.
"Citizens of the Philippines, Poland, Israel, and Turkey all have greater access to HCQ than American citizens do," observes AAPS General Counsel Andrew Schlafly. "In Venezuela, HCQ is available over the counter without a prescription, while in the United States pharmacists are prevented from filling prescriptions for HCQ."
AAPS rebuts arguments presented by the FDA, which implied that medications are approved as safe only for certain conditions. In fact, HCQ and most medications have been approved without limitation, such that physicians can prescribe them for any off-label use.
"The mortality rate from COVID-19 in countries that allow access to HCQ is only one-tenth the mortality rate in countries where there is interference with this medication, such as the United States," explains Andrew Schlafly.
Polish chemists have even showed the world how to synthesize HCQ from cheaply, widely available ingredients. The cost of this medication is less than a dollar a dose, in contrast with the very expensive alternatives being pushed by FDA officials.
In its filing, the FDA insisted that the public has no right to access nearly 100 million doses of HCQ which were donated to the Strategic National Stockpile. HHS is having that medication waste away while Americans are dying from COVID-19.
"In some areas of Central America, officials are even going door to door to distribute HCQ," Andrew Schlafly adds. "These countries have been successful in limiting the mortality from COVID-19 to only a fraction of what it is in wealthier countries."
This drug is being used by millions of people everyday with no reports of wide spread deaths only wide spread fear for one reason and one reason only, because it is connected to Donald Trump. Helluva reason to let people die needlessly.
https://www.prnewswire.com/news-rele...301098030.html
July 22, 2020 /PRNewswire/ -- This week the Association of American Physicians & Surgeons submitted additional evidence to a federal court for why interference with hydroxychloroquine (HCQ) should end by the Food & Drug Administration (FDA) and the Department of Health & Human Services (HHS), in AAPS v. FDA, No. 1:20-cv-00493-RJJ-SJB (W.D. Mich.).
"As confirmed by another recent study of thousands of patients at the Henry Ford Health System in Michigan, HCQ is both very safe and highly effective in treating COVID-19, reducing mortality by 50%," AAPS informed the court in its filing. "Countries with underdeveloped health care systems are using HCQ early and attaining far lower mortality than in the United States, where [HHS and the FDA] impede access to HCQ."
Yet most Americans are still unable to obtain HCQ for early treatment of COVID-19, and virtually no Americans are able to access it as preventive medicine. HCQ has been used safely for decades by travelers to protect against malaria, but Americans are dying from COVID-19 while HCQ is withheld from them.
"Citizens of the Philippines, Poland, Israel, and Turkey all have greater access to HCQ than American citizens do," observes AAPS General Counsel Andrew Schlafly. "In Venezuela, HCQ is available over the counter without a prescription, while in the United States pharmacists are prevented from filling prescriptions for HCQ."
AAPS rebuts arguments presented by the FDA, which implied that medications are approved as safe only for certain conditions. In fact, HCQ and most medications have been approved without limitation, such that physicians can prescribe them for any off-label use.
"The mortality rate from COVID-19 in countries that allow access to HCQ is only one-tenth the mortality rate in countries where there is interference with this medication, such as the United States," explains Andrew Schlafly.
Polish chemists have even showed the world how to synthesize HCQ from cheaply, widely available ingredients. The cost of this medication is less than a dollar a dose, in contrast with the very expensive alternatives being pushed by FDA officials.
In its filing, the FDA insisted that the public has no right to access nearly 100 million doses of HCQ which were donated to the Strategic National Stockpile. HHS is having that medication waste away while Americans are dying from COVID-19.
"In some areas of Central America, officials are even going door to door to distribute HCQ," Andrew Schlafly adds. "These countries have been successful in limiting the mortality from COVID-19 to only a fraction of what it is in wealthier countries."
This drug is being used by millions of people everyday with no reports of wide spread deaths only wide spread fear for one reason and one reason only, because it is connected to Donald Trump. Helluva reason to let people die needlessly.
- matchingmole
- 10-07-2020, 01:09 PM
Give half of his infected idiot squad some...and the other nine the treatment that he received...and see who lives.
- oeb11
- 10-07-2020, 04:08 PM
- oeb11
- 10-07-2020, 04:16 PM
Chloroquine or Hydroxychloroquine for COVID‐19: Is Cardiotoxicity a Concern?
Timothy J. Kamp
, Mohamed H. Hamdan
, and Craig T. January
Originally published28 May 2020https://doi.org/10.1161/JAHA.120.016887Journal of the American Heart Association. 2020;9
The severe acute respiratory syndrome coronavirus 2 viral pandemic causing coronavirus disease 2019 (COVID‐19) begs for rapid and innovative treatments. While most patients have mild symptoms, some will become critically ill and are straining existing clinical resources in many places around the world. In addition to flu like symptoms, acute cardiac manifestations in hospitalized patients in Wuhan, China, included cardiac injury (7.2%), shock (8.7%), and arrhythmia (16.7%).1
Several pharmacological therapies have been suggested including repurposing of existing drugs such as chloroquine and hydroxychloroquine, which were first developed in the World War II era for treatment and prophylaxis of malaria. These drugs were developed before modern drug safety surveillance programs, including the recognition that some drugs can cause long QT syndrome and the ventricular arrhythmia torsades de pointes. The concept that chloroquine might be effective in treating COVID‐19 viremia stems from in vitro work done during the severe acute respiratory syndrome era nearly 20 years ago. In February of this year, Chinese virologists reported that chloroquine and its less toxic derivative hydroxychloroquine could stop infection of severe acute respiratory syndrome coronavirus 2 in vitro.2 Emerging clinical trials from China and France suggest potential benefit using chloroquine or hydroxychloroquine, sometimes combined with the macrolide antibiotic azithromycin, to treat acute COVID‐19 patients resulting in more rapid reduction in viral shedding and possible improved clinical outcomes.3, 4 However, the available data are scant and far from conclusive at this point. There is growing interest in using these agents for treatment of acute COVID‐19 as well as for prophylaxis, with clinical trials underway around the world including the United States (see ClincialTrials.gov). Given limited treatment options for COVID‐19, off‐label use of chloroquine and hydroxychloroquine, sometimes with azithromycin, is currently widespread. Besides drug shortages and limiting the availability of the drugs for patients relying on them for treatment of some rheumatological disorders, is there the potential for other unanticipated adverse consequences?
Chloroquine and hydroxychloroquine were recognized as impacting the electrophysiological properties of the heart decades ago. Clinically, they can prolong the QT interval that could potentially initiate ventricular arrhythmias including torsades de pointes. Chloroquine is known to be an open channel blocker of the hERG 1A and 1A/1B potassium channel that in the heart underlies the repolarizing potassium current IKr; chloroquine binds to the common drug‐binding site in the channel pore. Block of IKr is the principal cause of drug‐induced long QT syndrome. Chloroquine also binds to cardiac sodium, calcium, and inward rectifier potassium channels to potentially cause QRS widening and conduction abnormalities. In a recent review of cardiac complications attributed to long‐term chloroquine or hydroxychloroquine use, cardiac conduction disorders and heart failure were the most common findings.5 The drugs have active metabolites and have relatively long elimination half‐lives—once given their drug effects and toxicities may take weeks to dissipate. In the Comprehensive In Vitro Proarrhythmia Assay initiative to develop approaches to test for drug‐induced torsades de pointes risk, chloroquine was included as the control “nonbalanced,” predominant hERG channel blocker, where it caused QT interval lengthening as well as mild PR and QRS widening.6 Additionally, chloroquine has a relatively narrow therapeutic window, with multiple cases of overdose leading to death from hemodynamic collapse or ventricular arrhythmias, and lethal overdose has recently been observed during this pandemic. Nevertheless, over >6 decades of use and millions of patients, the incidence of unanticipated sudden cardiac death is rarely reported except in cases of severe overdose. While chloroquine and hydroxychloroquine are older drugs whose development preceded modern thorough QT testing, their ability to prolong the QT interval does not appear to be associated with a substantial risk of sudden cardiac death and torsades de pointes.7 Despite this, caution is warranted in new applications using these drugs since most trials assessing their benefit did not study patients with cardiovascular comorbidities and disease where arrhythmia risk is the greatest.
Concern about azithromycin and increased cardiovascular death was raised in 2012 with the greatest risk in patients with underlying cardiovascular disease.8 The US Food and Drug Administration recognized this. Azithromycin can cause modest QT interval prolongation, but not through potent hERG channel blockade, rather when used chronically through an increase in peak and late cardiac sodium current to cause potential loading of cardiomyocytes with sodium and calcium to produce calcium overload.9
How should we proceed with the use of chloroquine and hydroxychloroquine, potentially combined with azithromycin, for COVID‐19 given that these agents bring some cardiac toxicity risk and their mechanisms for cardiac toxicity may not be the same? Is combining different and potentially additive mechanisms of cardiotoxicity wise? There are no available data from large randomized clinical trials defining dosing or duration of use for either prophylaxis or treatment of severe acute respiratory syndrome coronavirus 2 infection. Whether in clinical trials or for empiric off‐label treatment, some patients are at higher risk of cardiac arrhythmic complications and likely should not be candidates for these drugs including patients with a prolonged QT interval, patients with known or suspected congenital long QT syndrome, patients receiving other QT interval–prolonging drugs, patients with marked electrolyte disorders (particularly low serum potassium), and possibly patients with significant, untreated conduction abnormalities. It is reasonable to obtain a baseline ECG before treatment whenever possible to exclude a prolonged QT interval or advanced conduction system disease. In addition, critically ill patients receiving treatment need to be monitored by telemetry to detect serious arrhythmias. Clinicians should be alert for the potential of proarrhythmia drug effects. Nevertheless, given the overall safety profile of these quinolones, one can anticipate relatively little cardiac toxicity for a short course in noncritically ill patients and in prophylactic uses in the absence of underlying cardiac disease. However, in critically ill COVID‐19 patients, the risk of adverse cardiac events secondary to chloroquine and hydroxychloroquine is greater given the impact on the myocardium of cytokine storm from aggressive pulmonary infection as well as possible hypoxia in addition to the potential for viral myocarditis. How great the risk is relative to the benefit in critically ill patients with COVID‐19 will need to await the outcome of ongoing, controlled clinical trials. The emerging treatments for COVID‐19 require not only rapid implementation but thoughtful considerations to minimize unintended consequences including arrhythmias.
Timothy J. Kamp
, Mohamed H. Hamdan
, and Craig T. January
Originally published28 May 2020https://doi.org/10.1161/JAHA.120.016887Journal of the American Heart Association. 2020;9
The severe acute respiratory syndrome coronavirus 2 viral pandemic causing coronavirus disease 2019 (COVID‐19) begs for rapid and innovative treatments. While most patients have mild symptoms, some will become critically ill and are straining existing clinical resources in many places around the world. In addition to flu like symptoms, acute cardiac manifestations in hospitalized patients in Wuhan, China, included cardiac injury (7.2%), shock (8.7%), and arrhythmia (16.7%).1
Several pharmacological therapies have been suggested including repurposing of existing drugs such as chloroquine and hydroxychloroquine, which were first developed in the World War II era for treatment and prophylaxis of malaria. These drugs were developed before modern drug safety surveillance programs, including the recognition that some drugs can cause long QT syndrome and the ventricular arrhythmia torsades de pointes. The concept that chloroquine might be effective in treating COVID‐19 viremia stems from in vitro work done during the severe acute respiratory syndrome era nearly 20 years ago. In February of this year, Chinese virologists reported that chloroquine and its less toxic derivative hydroxychloroquine could stop infection of severe acute respiratory syndrome coronavirus 2 in vitro.2 Emerging clinical trials from China and France suggest potential benefit using chloroquine or hydroxychloroquine, sometimes combined with the macrolide antibiotic azithromycin, to treat acute COVID‐19 patients resulting in more rapid reduction in viral shedding and possible improved clinical outcomes.3, 4 However, the available data are scant and far from conclusive at this point. There is growing interest in using these agents for treatment of acute COVID‐19 as well as for prophylaxis, with clinical trials underway around the world including the United States (see ClincialTrials.gov). Given limited treatment options for COVID‐19, off‐label use of chloroquine and hydroxychloroquine, sometimes with azithromycin, is currently widespread. Besides drug shortages and limiting the availability of the drugs for patients relying on them for treatment of some rheumatological disorders, is there the potential for other unanticipated adverse consequences?
Chloroquine and hydroxychloroquine were recognized as impacting the electrophysiological properties of the heart decades ago. Clinically, they can prolong the QT interval that could potentially initiate ventricular arrhythmias including torsades de pointes. Chloroquine is known to be an open channel blocker of the hERG 1A and 1A/1B potassium channel that in the heart underlies the repolarizing potassium current IKr; chloroquine binds to the common drug‐binding site in the channel pore. Block of IKr is the principal cause of drug‐induced long QT syndrome. Chloroquine also binds to cardiac sodium, calcium, and inward rectifier potassium channels to potentially cause QRS widening and conduction abnormalities. In a recent review of cardiac complications attributed to long‐term chloroquine or hydroxychloroquine use, cardiac conduction disorders and heart failure were the most common findings.5 The drugs have active metabolites and have relatively long elimination half‐lives—once given their drug effects and toxicities may take weeks to dissipate. In the Comprehensive In Vitro Proarrhythmia Assay initiative to develop approaches to test for drug‐induced torsades de pointes risk, chloroquine was included as the control “nonbalanced,” predominant hERG channel blocker, where it caused QT interval lengthening as well as mild PR and QRS widening.6 Additionally, chloroquine has a relatively narrow therapeutic window, with multiple cases of overdose leading to death from hemodynamic collapse or ventricular arrhythmias, and lethal overdose has recently been observed during this pandemic. Nevertheless, over >6 decades of use and millions of patients, the incidence of unanticipated sudden cardiac death is rarely reported except in cases of severe overdose. While chloroquine and hydroxychloroquine are older drugs whose development preceded modern thorough QT testing, their ability to prolong the QT interval does not appear to be associated with a substantial risk of sudden cardiac death and torsades de pointes.7 Despite this, caution is warranted in new applications using these drugs since most trials assessing their benefit did not study patients with cardiovascular comorbidities and disease where arrhythmia risk is the greatest.
Concern about azithromycin and increased cardiovascular death was raised in 2012 with the greatest risk in patients with underlying cardiovascular disease.8 The US Food and Drug Administration recognized this. Azithromycin can cause modest QT interval prolongation, but not through potent hERG channel blockade, rather when used chronically through an increase in peak and late cardiac sodium current to cause potential loading of cardiomyocytes with sodium and calcium to produce calcium overload.9
How should we proceed with the use of chloroquine and hydroxychloroquine, potentially combined with azithromycin, for COVID‐19 given that these agents bring some cardiac toxicity risk and their mechanisms for cardiac toxicity may not be the same? Is combining different and potentially additive mechanisms of cardiotoxicity wise? There are no available data from large randomized clinical trials defining dosing or duration of use for either prophylaxis or treatment of severe acute respiratory syndrome coronavirus 2 infection. Whether in clinical trials or for empiric off‐label treatment, some patients are at higher risk of cardiac arrhythmic complications and likely should not be candidates for these drugs including patients with a prolonged QT interval, patients with known or suspected congenital long QT syndrome, patients receiving other QT interval–prolonging drugs, patients with marked electrolyte disorders (particularly low serum potassium), and possibly patients with significant, untreated conduction abnormalities. It is reasonable to obtain a baseline ECG before treatment whenever possible to exclude a prolonged QT interval or advanced conduction system disease. In addition, critically ill patients receiving treatment need to be monitored by telemetry to detect serious arrhythmias. Clinicians should be alert for the potential of proarrhythmia drug effects. Nevertheless, given the overall safety profile of these quinolones, one can anticipate relatively little cardiac toxicity for a short course in noncritically ill patients and in prophylactic uses in the absence of underlying cardiac disease. However, in critically ill COVID‐19 patients, the risk of adverse cardiac events secondary to chloroquine and hydroxychloroquine is greater given the impact on the myocardium of cytokine storm from aggressive pulmonary infection as well as possible hypoxia in addition to the potential for viral myocarditis. How great the risk is relative to the benefit in critically ill patients with COVID‐19 will need to await the outcome of ongoing, controlled clinical trials. The emerging treatments for COVID‐19 require not only rapid implementation but thoughtful considerations to minimize unintended consequences including arrhythmias.
- oeb11
- 10-07-2020, 04:17 PM
HC and OHHC have low therapeutic index - and great care must be used to not overdose 'teh' patient.
Used for long years in lupus treatment - the drugs can be beneficial - but must be used carefully by physicians
Leave out Moles!!!!LOL
Used for long years in lupus treatment - the drugs can be beneficial - but must be used carefully by physicians
Leave out Moles!!!!LOL
- Levianon17
- 10-07-2020, 04:20 PM
- matchingmole
- 10-07-2020, 04:25 PM
HC and OHHC have low therapeutic index - and great care must be used to not overdose 'teh' patient.
Used for long years in lupus treatment - the drugs can be beneficial - but must be used carefully by physicians
Leave out Moles!!!!LOL Originally Posted by oeb11
When the lupus pandemic hits...good luck
- skirtchaser79411
- 10-07-2020, 05:14 PM
but he had some bleach nd black light treatment
- HedonistForever
- 10-07-2020, 06:27 PM
- skirtchaser79411
- 10-07-2020, 06:42 PM
no i care hate the fat orange bastard but he will gone soon
- adav8s28
- 10-07-2020, 10:18 PM
They know the hydroxychloroquine only works for some CV19 patients. So, his doctors at Walter Reed gave Trump the cocktail of antibodies from Regeneron (stock price 587/share) and the Remidivir. Only 300 people have ever been given the cocktail of antibodies. Trump is the only person that has gotten both.
- oeb11
- 10-08-2020, 05:17 PM
'a' - care to share a reference on that allegation???
Prove what you state is factual
No way - DPSTs prefer to Lie - it is your default setting.
Prove what you state is factual
No way - DPSTs prefer to Lie - it is your default setting.